Announcements & Publications
News
September 21, 2021
Goldilocks Therapeutics, Inc. was awarded a $300K Phase I Small Business Innovation Research (SBIR) grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH) entitled: “Efficacy and pharmacokinetic assessment of renal-targeted therapy in a pig model of cisplatin induced acute kidney injury.” This work is designed to provide the first large-animal proof-of-concept showing efficacy using the Company’s mesoscale nanoparticle (MNP) platform. It is estimated that over 100,000 cancer patients in the U.S. receive cisplatin annually; about 30% of these individuals develop AKI, which interferes with their ability to receive optimal chemotherapy. Goldilocks’ Principal Investigator for this grant is Associate Director of Research Chintan Kapadia, Ph.D. under Award Number R43DK131669.
November 17, 2020
Goldilocks Therapeutics presents at the (virtually held) Life Sciences Summit 2020.
To access the 7-minute video, please click on the “play” icon below.
Presentations
Goldilocks CEO Arthur Klausner presented at the BIO CEO conference in New York City on February 12, 2020. The slide deck can be found here.